Trials / Recruiting
RecruitingNCT07532902
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
A Phase 1a/1b Basket Trial of BMS-986504 With Standard-of-Care Therapy For Patients With Select Metastatic MTAP-deleted Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study to test the safety of BMS-986504 in combination with standard disease-specific anticancer medication in people with metastatic/advanced unresectable MTAP-deleted solid tumor cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986504 | BMS-986504 PO daily |
| DRUG | Ipilimumab | Ipilimumab (1mg/kg Q6wk) |
| DRUG | Nivolumab | Nivolumab (360mg flat dose Q3wk) |
| DRUG | 5-FU | are continued until disease progression or intolerance |
| DRUG | Leucovorin | are continued until disease progression or intolerance |
| DRUG | Oxaliplatin | are continued until disease progression or intolerance |
| DRUG | Gemcitabine | Gemcitabine are given for a maximum of 6 cycles |
| DRUG | Platinum | Platinum are given for a maximum of 6 cycles |
Timeline
- Start date
- 2026-04-07
- Primary completion
- 2029-04-01
- Completion
- 2029-04-01
- First posted
- 2026-04-16
- Last updated
- 2026-04-16
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07532902. Inclusion in this directory is not an endorsement.